Northpond Ventures co-leads US$55 million Series A financing round for Triumvira Immunologics

On August 27, 2020, Triumvira Immunologics Inc. successfully completed a US$55 million Series A financing round. The financing was co-led by Northpond Ventures, LLC and Leaps by Bayer, the impact investment unit of Bayer AG. Additional investors include Oceanpine Capital and Viva Biotech Holdings, and existing investors include Bloom Burton & Co. and the Centre for Commercialization of Cancer Immunotherapy (C3i).

Triumvira is a US-based, privately-held biopharmaceutical company with operations both in the US and Canada.  The company is developing a novel platform for engineering T-cells to attack cancers.

Northpond, headquartered in the US, is a leading global science, medical, and technology-driven venture firm dedicated to building and empowering breakthrough companies in life sciences and technology. Northpond has in excess of $1 billion of committed capital, with over 21 businesses represented in its portfolio.

Gowling WLG was Canadian counsel to Northpond on certain aspects of this financing with a team led by Derek Keay and including Garrett Hamel, Anita Nador and Lorne Segal.